Moore Capital Management LP Buys Shares of 189,256 Boston Scientific Corporation $BSX

Moore Capital Management LP bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 189,256 shares of the medical equipment provider’s stock, valued at approximately $8,077,000.

Several other hedge funds have also bought and sold shares of the stock. Brighton Jones LLC boosted its position in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the last quarter. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the second quarter valued at $26,000. Main Street Financial Solutions LLC lifted its stake in Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after purchasing an additional 1,971 shares during the last quarter. Ieq Capital LLC boosted its holdings in Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after acquiring an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC boosted its stake in shares of Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after purchasing an additional 2,556 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

BSX has been the topic of several research reports. Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a report on Wednesday, July 29th. Canaccord Genuity Group cut their price objective on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a research report on Thursday, May 28th. Argus restated a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Finally, TD Cowen reissued a “buy” rating and issued a $56.00 target price on shares of Boston Scientific in a research report on Tuesday, August 25th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Buying and Selling

In other news, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have bought 194,522 shares of company stock worth $9,385,210. Insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

NYSE:BSX opened at $46.82 on Monday. The stock has a market capitalization of $67.85 billion, a PE ratio of 18.96, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The stock’s 50-day moving average price is $46.56 and its 200-day moving average price is $56.53. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has authorized a share buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.